MedTrace Logo

Bupropion in the Treatment of Methamphetamine Dependence

NCT00572234 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-10-10

Study results available
· View outcomes & findings →

Summary

Methamphetamine dependence is a significant drug use disorder in the Midwest. While a number of psychosocial and pharmacological treatments have been studied, no specific treatments for methamphetamine have been identified. This study is a collaborative pre-clinical and clinical partnership examining bupropion in the treatment of methamphetamine dependence.

Conditions

  • Methamphetamine Use Disorder

Interventions

DRUG

bupropion SR

12 week course of bupropion SR 150 mg, BID

Sponsors & Collaborators

  • University of Nebraska

    lead OTHER

Principal Investigators

  • Kathleen M Grant, MD · Veterans Affairs Medical Center, Omaha

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2010-04-06
Completion
2011-05-20

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00572234 on ClinicalTrials.gov